Pharmacotherapy of COVID-19: in vitro and in vivo application of remdesivir
Abstract
The coronavirus (SARS-CoV-2) is a pathogen that causes severe acute respiratory syndrome in humans (COVID-19). Its outbreak has engulfed the world suddenly, leading to a global pandemic crisis. This review article was designed to evaluate the existing evidence and experience related to an already-approved pharmacologic agent called remdesivir. PubMed, Scopus, Web of Science, and SCIELO databases were used to search for word-combinations, such as “COVID-19 AND Remdesivir” or “SARS-CoV-2 AND
Remdesivir”. Four reviewers independently searched results and abstracted data from selected studies up to March 21. Remdesivir has been shown to inhibit SARS-CoV-2, in vitro and in vivo, with therapeutic potential in treating patients hospitalized with COVID-19. However, it has been associated with the
development of adverse effects.
Keywords
Full Text:
PDF (Português (Brasil))DOI: http://dx.doi.org/10.14450/2318-9312.v34.e1.a2022.pp45-57
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Mariana de Almeida Rosa Rezende, Alice Ferreira Cordeiro, Andrey Paradela de Sousa, Isadora Valério da Silveira
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Infarma - Ciências Farmacêuticas
ISSN - 2318-9312 (Versão eletrônica)
ISSN - 0104-0219 (Versão impressa)
Conselho Federal de Farmácia - CFF
SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF
CEP: 71635-615 - Fone: (61)3878-8751
e-mail:infarma@cff.org.br
Diretoria
Walter da Silva Jorge João, Presidente do Conselho Federal de Farmácia
Lenira da Silva Costa, Vice-Presidente do Conselho Federal de Farmácia
João Samuel de Morais Meira, Tesoureiro do Conselho Federal de Farmácia
Luiz Gustavo de Freitas Pires, Secretário-Geral do Conselho Federal de Farmácia